Literature DB >> 11395610

Role of protein kinase C and phosphatases in the pulmonary vasculature of neonatal piglets.

J W Berkenbosch1, J Baribeau, E Ferretti, T Perreault.   

Abstract

OBJECTIVE: Persistent pulmonary hypertension of the newborn is characterized by the presence of intense vasoconstriction and vascular remodeling. Protein tyrosine phosphorylation has been recognized as a critical regulatory element in signal transduction, because it is dynamically regulated by the opposing actions of protein tyrosine kinases and protein tyrosine phosphatases. The objectives of this study were to investigate the role of protein kinase C and phosphatases in the neonatal pulmonary vasculature of normoxic and chronically hypoxic piglets.
DESIGN: Prospective, randomized, unblinded study.
SETTING: Hospital research laboratory.
SUBJECTS: Newborn Yorkshire-Landrace piglets.
INTERVENTIONS: Normoxic animals were 3-6 days old. Hypoxic animals were exposed to hypoxia (Fio2 0.10) between 1 and 15 days of age to induce pulmonary hypertension and then were studied.
MEASUREMENTS AND MAIN RESULTS: In isolated perfused lungs from normoxic piglets, we measured the perfusion pressure to assess the vasoconstrictor response to protein kinase C activation with phorbol 12,13-dibutyrate or 1-oleyl-2-acetyl-glycerol. We also assessed the effect of protein kinase C inhibition with staurosporine (2 x 10-6M) and chelerythrine (5 x 10-5M) on endothelin-1-induced pulmonary vasoconstriction. We then examined the effect of chelerythrine and phosphatase inhibition with phenylarsine oxide on the baseline perfusion pressure of normoxic and chronically hypoxic piglets. Phorbol 12,13-dibutyrate and 1-oleyl-2-acetyl-glycerol caused a sustained, dose-dependent increase in perfusion pressure, with relative potencies about 100- and 1000-fold less than endothelin-1, respectively. Protein kinase C inhibitors, chelerythrine and staurosporine, decreased the constrictor response to endothelin-1. Chelerythrine did not affect baseline perfusion pressure in the normoxic animal, whereas it lowered pulmonary vascular tone in chronically hypoxic animals. With respect to phosphatases, phenylarsine oxide significantly increased perfusion pressure in normoxia as well as in hypoxia.
CONCLUSIONS: These findings confirm that protein kinase C activation causes sustained vasoconstriction in the neonatal pulmonary vasculature and mediates the vasoconstrictor action of potent peptides, like endothelin-1. These findings also confirm that protein kinase C activation could be induced by hypoxic exposure in the neonatal piglet pulmonary vasculature. Phosphatases appear to modulate pulmonary vascular tone in the normoxic and hypoxic newborn piglet.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11395610     DOI: 10.1097/00003246-200106000-00030

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  4 in total

1.  Reactive oxygen species scavengers improve voltage-gated K(+) channel function in pulmonary arteries of newborn pigs with progressive hypoxia-induced pulmonary hypertension.

Authors:  Candice D Fike; Judy L Aschner; Mark R Kaplowitz; Yongmei Zhang; Jane A Madden
Journal:  Pulm Circ       Date:  2013-11-20       Impact factor: 3.017

2.  Changes of protein kinase Calpha and cyclin D1 expressions in pulmonary arteries from smokers with and without chronic obstructive pulmonary disease.

Authors:  Min Xaing; Xiansheng Liu; Daxiong Zeng; Ran Wang; Yongjian Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-04-21

3.  PKCβ and reactive oxygen species mediate enhanced pulmonary vasoconstrictor reactivity following chronic hypoxia in neonatal rats.

Authors:  Joshua R Sheak; Simin Yan; Laura Weise-Cross; Rosstin Ahmadian; Benjimen R Walker; Nikki L Jernigan; Thomas C Resta
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-01-10       Impact factor: 4.733

4.  Oxidative Stress and Therapeutic Development in Lung Diseases.

Authors:  Leah Villegas; Timothy Stidham; Eva Nozik-Grayck
Journal:  J Pulm Respir Med       Date:  2014-07-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.